| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.00091 | 1 |